Immediate versus delayed facilitated percutaneous coronary intervention: a pilot study
- PMID: 15965359
- DOI: 10.1097/01.fjc.0000164089.96445.d8
Immediate versus delayed facilitated percutaneous coronary intervention: a pilot study
Abstract
The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied patients have successful reperfusion and TIMI-3 flow and our data may not apply to patients with TIMI 0-2 flow.
Similar articles
-
Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings.J Thromb Thrombolysis. 2006 Apr;21(2):147-57. doi: 10.1007/s11239-006-5733-z. J Thromb Thrombolysis. 2006. PMID: 16622610 Clinical Trial.
-
Facilitated primary coronary intervention with abciximab and very low dose of alteplase during off-hours compared with direct primary intervention during regular hours.Catheter Cardiovasc Interv. 2005 Aug;65(4):484-91. doi: 10.1002/ccd.20427. Catheter Cardiovasc Interv. 2005. PMID: 15973688
-
Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study.Catheter Cardiovasc Interv. 2004 Aug;62(4):445-52. doi: 10.1002/ccd.20101. Catheter Cardiovasc Interv. 2004. PMID: 15274152 Clinical Trial.
-
Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.Am J Cardiovasc Drugs. 2003;3(5):381-6. doi: 10.2165/00129784-200303050-00011. Am J Cardiovasc Drugs. 2003. PMID: 14728074 Review.
-
Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.Atherosclerosis. 2012 Jun;222(2):426-33. doi: 10.1016/j.atherosclerosis.2012.02.041. Epub 2012 Mar 7. Atherosclerosis. 2012. PMID: 22483166 Review.
Cited by
-
Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings.J Thromb Thrombolysis. 2006 Apr;21(2):147-57. doi: 10.1007/s11239-006-5733-z. J Thromb Thrombolysis. 2006. PMID: 16622610 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous